Semler Scientific : November 2021 Presentation 2.2 MB

NASDAQ:SMLR

November 2021

Forward-Looking Statements

This presentation includes statements that are, or may be deemed, "forward-looking statements." In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believe," "estimate," "anticipate," "expect," "plan," "intend," "may," "could," "might," "will," "should," or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. Such forward-looking statements appear in a number of places throughout this presentation and include statements regarding our expectations regarding revenue and net income growth, growth in operating expenses, stockholder dilution, and continued generation of cash from operations and profitability as well as statements regarding our expanding product offering. These statements are based on our current intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the impact of healthcare reform (including the Affordable Care Act) on our business, the effect of new financial incentives for medical providers and the amount of such payments, our ongoing and planned development of products, the timing of launch of such new products, the strength and breadth of our intellectual property, the degree of clinical utility and adoption of our product, particularly for specific patient populations, and the success of new service models.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, our expected financing needs and sources of financing, the industry in which we operate and the trends that may affect the industry or us. Our results of operations, financial condition, liquidity, prospects, growth and strategies depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that forward- looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this presentation as a result of, among other factors, the factors referenced in the "Risk Factors" section of our Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 9, 2021 and as may be amended from time to time and the effects of the COVID-19 pandemic, including our assumptions regarding its duration and the impact on use of our products and services. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this presentation, they may not be predictive of results of developments in future periods. Any forward-looking statements that we make in this presentation speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this presentation, except as required by law.

You should read carefully our "Cautionary Note Regarding Forward-Looking Statements and Industry Data" and the factors described in the "Risk Factors" sections of the Annual Report to better understand the risks and uncertainties inherent in our business.

2

Disruptive, Paradigm-shifting Business

Technology to bring Peripheral Arterial Disease (PAD) testing to the front lines of medicine (primary care, home assessment, etc.)

High-leverage distribution model selling to and working through Health Insurance Plans and Risk Assessment companies

Software as a service (SAAS) revenue models:

• recurring-revenuesubscription licensing model
• variable-fee(fee-per-test) licensing model

3

Investment Highlights

(in millions of U.S. Dollars)

• Solid track record of revenues

and net income since Q4 2017

	2018		2019*		2020**		Thru 9/2021***

•	Recurring revenue model
•	Strong cash generation

• Income tax benefit of $4.4M primarily due to release of tax valuation allowance
• Covid-19impacted annual results

***Delta variant may have impacted Q3 2021 results

$38.6	$41.5
$32.8
$21.5		$10.7	$16.0	$17.7
		$5.3

REVENUESOPERATING INCOME

$15.1

$14.0

$15.7

$5.0

NET INCOME

4

Semler Scientific

Solutions to Improve Healthcare for Age 50 and Over

5